Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Titel:
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Auteur:
Kaul, Inder Sawchak, Sharon Correll, Christoph U Kakar, Rishi Breier, Alan Zhu, Haiyuan Miller, Andrew C Paul, Steven M Brannan, Stephen K